Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ: BIIB )

298.66 +1.53 (+0.51%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Biogen Idec

< Previous 1 2 3 4 Next >
BIOGEN ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Biogen, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Biogen Shareholder Alert
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
CORRECTING and REPLACING Shareholder Alert: Robbins LLP Informs Investors Biogen, Inc. (BIIB) is Being Sued for Misleading Shareholders
From Robbins LLP
Via Business Wire
Shareholder Alert: Robbins LLP Informs Investors Biogen, Inc. (BIIB) is Being Sued for Misleading Shareholders
From Robbins LLP
Via Business Wire
Biogen Leads From the Top With Disability Inclusion
SOURCE: Biogen 
Via 3BL Media
Biogen Deadline Alert
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Sage Therapeutics and Biogen Announce New Analyses from the LANDSCAPE Clinical Development Program of Zuranolone in MDD Presented at the American College of Neuropsychopharmacology (ACNP) Congress
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics and Biogen Announce Positive, One-Year Zuranolone 50 mg Data in the Ongoing Open-Label SHORELINE Study in Patients with MDD
From Sage Therapeutics, Inc.
Via Business Wire
From Pause to Pride: A Mother's Journey
SOURCE: Biogen 
Via 3BL Media
Topics LGBTQ
Exposures Diversity
Introducing Biogen's 2021 Diversity, Equity & Inclusion Report
SOURCE: Biogen 
Via 3BL Media
MSM Students to Participate in Biogen's Summer Health Equity Fellowship Program
SOURCE: Biogen 
Via 3BL Media
Youth Neurology Program: Building a More Diverse Neurology Workforce
SOURCE: Biogen 
Via 3BL Media
Exposures COVID-19
Wanda Castro-Borrero: Carrying on Legacy of Care
SOURCE: Biogen 
Via 3BL Media
Topics LGBTQ
Exposures Diversity
Global Cancer Therapy Market Expected to Reach $268 Billion In 2026, With A CAGR Of 9.15%
Palm Beach, FL –November 16, 2021 – FinancialNewsMedia.com News Commentary – The COVID-19 pandemic has affected the healthcare systems globally and also has a significant impact on the cancer therapy... 
Via FinancialNewsMedia
Exposures COVID-19
Enel X Collaborates With Biogen to Electrify Take-Home Vehicle Fleet in North America
SOURCE: Biogen 
Via 3BL Media
Topics Climate Change Economy Electric Vehicles
Exposures Climate Economy Electric Vehicles
Kenan Fellows Program and Biogen Foundation Collaborate to Advance Workforce Education
SOURCE: Biogen 
Via 3BL Media
Biogen Sets Industry Record with Recognition on Dow Jones Sustainability World Index for 9th Consecutive Year
SOURCE: Biogen 
Via 3BL Media
Topics Climate Change Stocks Supply Chain
Exposures COVID-19 Climate Supply Chain
CEO Climate Alliance to World Leaders: We Support You in Taking Decisive Climate Steps at COP26
SOURCE: Biogen 
Via 3BL Media
Topics Emissions
Biogen Launches Supplier Climate Action Program “Energize” With Leading Pharmaceutical Companies
SOURCE: Biogen 
Via 3BL Media
Topics Climate Change Supply Chain
Exposures Climate Supply Chain
A Letter From Alphonse Galdes, Ph.D., Head of Pharmaceutical Operations and Technology at Biogen: It's Time for Companies to Act Like the Climate Crisis Is a Health Crisis
SOURCE: Biogen 
Via 3BL Media
Topics Climate Change Death Emissions
Exposures Climate Death Supply Chain
MIT Collaborates With Biogen on Three-Year, $7 Million Initiative to Address Climate, Health, and Equity
SOURCE: Biogen 
Via 3BL Media
Topics Climate Change
Exposures Climate
Sage Therapeutics and Biogen Announce Plans to Submit a New Drug Application (NDA) for Zuranolone to the U.S. Food & Drug Administration in the Second Half of 2022 with Rolling Submission Expected to Start in Early 2022
From Sage Therapeutics, Inc.
Via Business Wire
Healthy Climate, Healthy Lives: Advancing Strategic Collaborations
SOURCE: Biogen 
Via 3BL Media
Topics Emissions
Healthy Climate, Healthy Lives: Engaging Employees and Suppliers
SOURCE: Biogen 
Via 3BL Media
Topics Emissions
Healthy Climate, Healthy Lives: Fossil Fuel Free Operations
SOURCE: Biogen 
Via 3BL Media
Topics Emissions
Global Atopic Dermatitis Treatment Market Size Is Projected To Be Worth US$21.80 Billion By 2026
Palm Beach, FL –October 12, 2021 – FinancialNewsMedia.com News Commentary – Atopic Dermatitis is an inflammatory skin disease, and the degree of its severity varies from patient to patient. It usually... 
Via FinancialNewsMedia
Biogen Issues First Progress Report of its Signature Healthy Climate, Healthy Lives™ Initiative
SOURCE: Biogen 
Via 3BL Media
Topics Emissions Supply Chain
Exposures Supply Chain
Alzheimer’s Treatment Market Is Anticipated To Reach $2 Billion By The End Of 2027
Via FinancialNewsMedia
Topics Death
Exposures Death
Sage Therapeutics and Biogen Announce Positive Pivotal Phase 3 Results for Zuranolone, an Investigational Two-Week, Once-Daily Therapeutic Being Evaluated for Major Depressive Disorder
From Sage Therapeutics, Inc.
Via Business Wire
Biogen and Eisai Launch Multiple Initiatives to Help Patients With Alzheimer's Disease Access ADUHELM™
SOURCE: Biogen 
Via 3BL Media
Topics Intellectual Property
Exposures COVID-19 Intellectual Property Product Safety
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.